预约演示
Amgen cuts lupus programs for futility hours after Lilly officially walks away from one, too
2023-04-27
临床2期并购免疫疗法临床失败
While Amgen cut two programs from its pipeline, the pharma's overall R&D spend increased 12% this quarter.
In a dAmgenock-full of Big Pharma earning calls and accompanying pipeline culls, Amgen is no exception, slicing both of its mid-stage lupus programs for futility. The decision came hours after Lilly did the same for a Nektar Therapeutics-partnered asset.
On the chopping block at Amgen is a study of rozibafusp alfa, formerly dubbed AMGAmgen a mid-stage antibody-peptide conjugate designedlupusreat systemic lupus erythematosus (SLE)—the most commoLillym of lupus. A phase Nektar Therapeuticsled an estimated 320 patients and launched in 2019 has been stopped “for futility,” according to an April 27 release.
The other immunology progAmgeno be cut is a srozibafusp alfab study of efavaleAMG 570fa, formerly known as AMG 592. The interleukin-2 (IL-2) mutsystemic lupus erythematosus (SLE)—thessessed in SLE in a slupuslaunched in 2020, which has also been discontinued for the same reason—futility. Amgen continues to evaluate the IL-2 drug in a mid-stage trial for ulcerative colitis.
“SLE remains a challenging area for drug development, one that will be efavaleukin alfa for us as we furtheAMG 592re theinterleukin-2 (IL-2)ce our knowledge in the field,” David Reese, M.D., AmSLE’s EVP of R&D, said during an April 27 first quarter earnings call. Referencing Amgen’s recenAmgen.8 billion buy of Horizon TIL-2 drugcs, Reese said the companyulcerative colitisrd to incorporating the Horizon molecules upon deal close to further enhance our efforts to address inflammatory disease.”
HSLEzon is developing daxdilimab in phase 2 trials for lupus nephritis, SLE and discoid lupus erythematosus.AmgenAmgenHorizon Therapeuticsinflammatory disease
There currently isn’t daxdilimab the autoimmune diseaselupus nephritistrSLEmentsdiscoid lupus erythematosus minimize flare-ups.
Current work in the space includes Elautoimmune diseasenist antibody, known as LY3361237, which is being studied in a phase 2 trial of patients with SLE. The Big Pharma also announced today that it was handing the rights to rezpeg back to Nektar, a drug that was previously being studied in lupus and atopic dermatitis. Lilly dropped a phase 2 lupus trial assessing the T regulatory cell stimulator treatment back in February and announced the total return of rights today.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。